Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Visit

ASCO 2023 | ASC2ESCALATE: Phase II dose-escalation study of second-line asciminib in patients with CML-CP

Jorge Cortes • 9 Jun 2023

ASCO 2023

Chronic Myeloid Leukemia Leukemia Asciminib

ASC2ESCALATE

Jorge Cortes, MD, Augusta University, Augusta, GA, describes the rationale and aims of the Phase II ASC2ESCALATE study (NCT05384587) evaluating the safety and efficacy of asciminib in the second-line setting with dose-escalation in patients with chronic myeloid leukemia in chronic phase (CMP-CP) who do not achieve BCR:ABL1IS ≤ 1% at 6 months.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Disclosures

Consultant for Pfizer, Novartis, Takeda, Sun Pharma, Rigel and Forma Therapeutics. Dr Cortes’ institution receives research support from Pfizer, Takeda, Novartis and Sun Pharma.

Key emerging trials in CML and the importance of improving treatment-free remission rates

Jorge Cortes • 7 Sep 2023

Social determinants of health & their impact on patients with hematological malignancies

Jorge Cortes • 7 Sep 2023

Post-hoc analysis of OPTIC: patient responses to ponatinib by T315I mutational status

Jorge Cortes • 7 Sep 2023

Exciting updates in the field of CML: disease pathophysiology & novel agents

Jorge Cortes • 7 Sep 2023

Related Videos

The role of CPX-351 in the AML treatment landscape & insights into the AMLSG 30-18 trial

Felicitas Thol • 19 Apr 2024

Integrating genomics and MRD in transplant decision-making for patients with AML

Jurjen Versluis • 22 Apr 2024

Blinatumomab to achieve remission and consolidation with haploSCT for pediatric ALL

Alberto Olaya-Vargas • 15 Apr 2024

Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS

Sridhar Chaganti • 16 Apr 2024